UGT2B10: A Potential Drug Target Or Biomarker (G7365)

Target Name: UGT2B10

NCBI ID: G7365

UGT2B10

UGT2B10: A Potential Drug Target Or Biomarker

UGT2B10 (MGC142209) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, diabetes, and neurodegenerative disorders. The UGT2B10 gene is located on chromosome 6p21 and encodes a protein known as UGT2B10.

The UGT2B10 gene has been shown to play a role in the detoxification of many classes of drugs, including some anti-cancer drugs. It is also involved in the metabolism of several drugs used to treat diabetes, such as metformin and Shanluxin. Additionally, UGT2B10 has been implicated in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

One of the main reasons for the potential drug targeting of UGT2B10 is its involvement in drug metabolism and its effects on drug levels in the body. UGT2B10 is known to be an enzyme that is expressed in many tissues throughout the body, including the liver, lung , and kidney. It is also shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its potential drug targeting properties, UGT2B10 is also a potential biomarker for several diseases. For example, it has been shown to be a potential biomarker for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, UGT2B10 has been shown to be a potential biomarker for cancer, including breast, ovarian, and colorectal cancer.

Another promising aspect of UGT2B10 is its potential to be used as a therapeutic target in combination with other treatments. For example, UGT2B10 has been shown to be involved in the metabolism of the chemotherapy drug doxorubicin, which is often used to treat breast cancer. doxorubicin is known to be metabolized by UGT2B10, and studies have shown that inhibiting UGT2B10 activity can significantly reduce the levels of doxorubicin in the body, leading to improved drug efficacy.

Furthermore, UGT2B10 has also been shown to be involved in the metabolism of other drugs used to treat diabetes, such as metformin and Shanluxin. Therefore, UGT2B10 may be a potential target for drugs used to treat diabetes, and it is a potential biomarker for diabetes and other diseases.

In conclusion, UGT2B10 is a gene that has the potential to be a drug target or biomarker for various diseases, including cancer, diabetes, and neurodegenerative disorders. Its involvement in drug metabolism and its potential as a therapeutic target make it an attractive candidate for further research. Further studies are needed to fully understand the role of UGT2B10 in disease progression and the development of new treatments.

Protein Name: UDP Glucuronosyltransferase Family 2 Member B10

Functions: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds

The "UGT2B10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets